Prolonged improvement of raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy
- 1 February 1990
- journal article
- case report
- Published by Wiley in Arthritis & Rheumatism
- Vol. 33 (2) , 274-276
- https://doi.org/10.1002/art.1780330218
Abstract
We describe a patient with systemic sclerosis (SSc; scleroderma) characterized by severe Raynaud's phenomenon, cutaneous sclerosis, and digital ulceration and subsequent amputation who was treated with recombinant tissue plasminogen activator (rt‐PA) after acute myocardial infarction. She showed prompt improvement of the Raynaud's phenomenon and healing of the digital ulceration. After 18 months of followup, the Raynaud's phenomenon has remained mild, and there has been improvement in the cutaneous sclerosis. Since the pathophysiology of SSc has been associated with disorders of fibrinolysis and coagulation, this patient represents an interesting index case that might prompt further evaluation of rt‐PA therapy in carefully selected patients.Keywords
This publication has 8 references indexed in Scilit:
- Thrombolytic Agents in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- 158 Tissue plasminogen activator (t-PA) in the treatment of digital ischaemia in systemic sclerosis (SS): Further observationsFibrinolysis, 1988
- Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell functionComparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1988
- Cytotoxicity of sera from patients with sclerodermaArthritis & Rheumatism, 1983
- D-Penicillamine Therapy in Progressive Systemic Sclerosis (Scleroderma)Annals of Internal Medicine, 1982
- Endothelial injury in scleroderma.The Journal of Experimental Medicine, 1979
- Arterial thrombosis in sclerodermaBritish Journal of Dermatology, 1975
- Pathogenesis of systemic sclerosis: A vascular hypothesisSeminars in Arthritis and Rheumatism, 1975